# OnCo record nct05730036 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05730036/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05730036", "NCT05730036" ;
  schema:name "A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Re"@en ;
  schema:alternateName "LINKER-MM3"@en ;
  schema:description "A phase 3 trial of Linvoseltamab, Elotuzumab, Pomalidomide in multiple myeloma, run by Regeneron Pharmaceuticals, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05730036/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05730036> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2023-09-18" ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/>, <https://onco.cc/cancers/myeloma-relapsed-refractory/> ;
  onco:technologies <https://onco.cc/technologies/antiemetic-therapy/>, <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/technologies/protac-degrader/>, <https://onco.cc/technologies/t-cell-engager/> ;
  onco:drugs <https://onco.cc/drugs/linvoseltamab/>, <https://onco.cc/drugs/elotuzumab/>, <https://onco.cc/drugs/pomalidomide/>, <https://onco.cc/drugs/dexamethasone/> ;
  onco:companies <https://onco.cc/companies/regeneron/> .